$1.33-14.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
Just reported
From Aardvark Therapeutics, Inc.'s results release of November 13, 2026; its quarterly report has since been filed.
Actual
$0.00
Guided
—
No guide given
Actual
-$0.88
Guided
—
No guide given
Actual
-$19.7M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$19.2M | -$16.3M | -17.59% |
| Profit per share | -$0.88 | -$0.75 | -17.33% |
| Free Cash Flow | -$13.5M | -$11.4M | -18.86% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Aardvark Therapeutics, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The lifting of the clinical hold and the FDA’s agreement that we may conduct an open-label trial at 200 mg twice daily are important steps toward resuming clinical development of ARD-101 in PWS,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aardvark Therapeutics, Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.